OverviewSuggest Edit

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. The Company's purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
TypePublic
Founded2002
HQSouth Brunswick Township, NJ, US
Websitecytosorbents.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Sept 2017)65
Revenue (FY, 2017)$15.2 M(+60%)
Share Price (Jun 2021)$8.2(+3%)
Cybersecurity ratingAMore

Key People/Management at Cytosorbents

Phillip P. Chan

Phillip P. Chan

Chief Executive Officer and President
Alan D. Sobel

Alan D. Sobel

Director
Kathleen Bloch

Kathleen Bloch

Chief Financial Officer
Vincent Capponi

Vincent Capponi

Chief Operating Officer
Show more

Cytosorbents Office Locations

Cytosorbents has offices in South Brunswick Township and Berlin
South Brunswick Township, NJ, US (HQ)
7 Deerpark Dr, Monmouth Junction
Berlin, DE
Müggelseedamm 131
Show all (2)

Cytosorbents Financials and Metrics

Cytosorbents Revenue

Embed Graph
View revenue for all periods
Cytosorbents's revenue was reported to be $15.15 m in FY, 2017 which is a 59% increase from the previous period.
USD

Revenue (FY, 2017)

15.2m

Revenue growth (FY, 2016 - FY, 2017), %

59%

Gross profit (FY, 2017)

9.6m

Gross profit margin (FY, 2017), %

63.6%

Net income (FY, 2017)

(8.5m)

EBIT (FY, 2017)

(9.8m)

Market capitalization (4-Jun-2021)

353.9m

Closing stock price (4-Jun-2021)

8.2

Cash (31-Dec-2017)

17.3m

EV

346.6m
Cytosorbents's current market capitalization is $353.9 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

4.8m9.5m15.2m

Revenue growth, %

99%59%

Cost of goods sold

2.2m4.0m5.5m

Gross profit

2.6m5.6m9.6m
USDFY, 2015FY, 2016FY, 2017

Cash

5.3m5.2m17.3m

Accounts Receivable

648.9k1.4m2.2m

Prepaid Expenses

511.9k315.8k416.0k

Inventories

1.2m834.0k795.7k
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1m)(11.8m)(8.5m)

Depreciation and Amortization

113.0k161.6k218.3k

Inventories

(671.3k)340.4k57.3k

Accounts Payable

(83.2k)2.1m523.4k
USDFY, 2015

Financial Leverage

1.4 x
Show all financial metrics

Cytosorbents Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Cytosorbents Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Cytosorbents Online and Social Media Presence

Embed Graph

Cytosorbents News and Updates

CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit

MONMOUTH JUNCTION, N.J., May 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the...

CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Traumatic Injury

MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat deadly conditions in critically-ill and cardiac surgery patients around the world,...

CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference

MONMOUTH JUNCTION, N.J., March 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...

CytoSorbents Reports Preliminary Fourth Quarter and Full Year 2020 Revenue

MONMOUTH JUNCTION, N.J., Jan. 12, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world,...

CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing

MONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world,...

CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference

MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...
Show more

Cytosorbents Blogs

CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications

Terri Anne Powers, IRC, experienced financial and communications professional, to strengthen and expand relationships with the investment and broader stakeholder community by building best-in-class investor relations and corporate communications function MONMOUTH JUNCTION, N.J., June 1, 2021 /PRNews…

CytoSorbents to Present at the Jefferies Virtual Healthcare Conference

MONMOUTH JUNCTION, N.J., May 27, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly conditions in critically ill and cardiac surgery patients around the world, announces that the Company will…

CytoSorb® Registered and Commercially Available in Singapore

CytoSorbents announces immediate commercial availability of CytoSorb in Singapore through distributor Humedical MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat de…

CytoSorbents Reports First Quarter 2021 Financial and Operational Results

Total revenue increased to $10.6M. Q1 2021 CytoSorb product sales grew 24% to $10.1M versus $8.2M a year ago MONMOUTH JUNCTION, N.J., May 4, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader using its CytoSorb® blood purification technology to treat life-threatening…

CytoSorbents to Report Q1 2021 Operating and Financial Results

MONMOUTH JUNCTION, N.J., April 27, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q…

U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., April 19, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U. approved CytoSorb® blood purification technology is intended to treat deadly conditions in critically-ill and cardiac surgery patients, announces that the U.S. F…
Show more

Cytosorbents Frequently Asked Questions

  • When was Cytosorbents founded?

    Cytosorbents was founded in 2002.

  • Who are Cytosorbents key executives?

    Cytosorbents's key executives are Phillip P. Chan, Alan D. Sobel and Kathleen Bloch.

  • How many employees does Cytosorbents have?

    Cytosorbents has 65 employees.

  • What is Cytosorbents revenue?

    Latest Cytosorbents annual revenue is $15.2 m.

  • What is Cytosorbents revenue per employee?

    Latest Cytosorbents revenue per employee is $233.1 k.

  • Who are Cytosorbents competitors?

    Competitors of Cytosorbents include Terumo, Kawasumi Laboratories and Hollister.

  • Where is Cytosorbents headquarters?

    Cytosorbents headquarters is located at 7 Deerpark Dr, Monmouth Junction, South Brunswick Township.

  • Where are Cytosorbents offices?

    Cytosorbents has offices in South Brunswick Township and Berlin.

  • How many offices does Cytosorbents have?

    Cytosorbents has 2 offices.